Allergy Thera signs Canadian drug rights to Nycomed
Allergy Therapeutics, a UK specialist pharmaceutical company focused on allergy vaccination, has signed an exclusive distribution agreement with privately-held Swiss drugmaker Nycomed's Canadian subsidiary for the local rights to its Pollinex R, an allergy vaccine for the treatment of allergic rhinitis due to ragweed pollen.
Additionally, the companies have agreed on an exclusive negotiation period for rights to Pollinex Quattro (Marketletters passim) in Canada for the treatment of grass, ragweed and tree allergies. Nycomed will support Allergy Therapeutics in its efforts to submit the dossier for Pollinex Quattro Grass in the first half of 2009.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze